[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-aging":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,65,0,25,[9,51,78,110,147,183,217,264,291,326,355,378,406,435,459,478,502,522,550,576,603,629,654,678,699],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100645084","evaluation-of-applex-apple-extract-on-anti-inflammatory-and-healthy-aging-effects-100645084",false,"NCT07678346","Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Anti-Inflammatory and Healthy Aging Effects of AppleX™ Apple Extract (15% Fisetin) in Adults 45-70 Years of Age","Inclusion Criteria:\n\n* Age 45-70 years at time of enrollment\n* Meets questionnaire-based inflammatory enrichment criteria (at least 2 of 5 risk factors, per Section 4.2)\n* Non-smoker (no tobacco or nicotine use within 6 months of enrollment)\n* Willing and able to maintain stable diet, exercise habits, and supplement use throughout the 24-week study period\n* No major medication changes planned during the study period\n* Willing to perform home-based DBS collections at T0, T12, and T24\n* Access to a smartphone or computer to complete eConsent and online questionnaires\n* Able to provide informed consent via the Alethios eConsent platform\n\nExclusion Criteria:\n\n* Current use of prescription anti-inflammatory medications including NSAIDs (regular use ≥3x\u002Fweek), corticosteroids, or DMARDs\n* Diagnosis of an autoimmune or inflammatory disease (e.g., rheumatoid arthritis, lupus, IBD, multiple sclerosis)\n* Active or unstable cardiovascular disease requiring medication changes during the study period\n* History of cancer within the past 5 years (except non-melanoma skin cancer)\n* Regular use of supplemental fisetin, quercetin, or resveratrol within 30 days of enrollment\n* Pregnancy, breastfeeding, or planning to become pregnant during the study\n* Known allergy to apple or apple-derived products\n* Body mass index (BMI) \\>40 kg\u002Fm²",true,"ALL","45 Years","70 Years",{"count":22,"type":23},70,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to learn if AppleX™ Apple Extract can help lower systemic inflammation in adults aged 45-70 with signs of low-grade inflammation. It will also look at the extract's effects on fatigue, joint comfort, and biological aging metrics.\n\nThe main questions it aims to answer are:\n\n* Does taking AppleX™ Apple Extract daily lower high-sensitivity C-reactive protein (hsCRP) levels, a key marker of inflammation in the blood?\n* Does AppleX™ Apple Extract improve participant-reported fatigue and joint comfort?\n* Does the extract slow down biological or epigenetic aging metrics compared to a placebo?\n\nResearchers will compare AppleX™ Apple Extract to a placebo (a look-alike capsule that contains no active ingredients) to see if the apple extract has a measurable anti-inflammatory and healthy aging effect.",[29,30,31,32],"Systemic Inflammation (hsCRP)","Healthy Aging","Vitality","Healthy Adult Participants",[34,35,36,37],"Apple extract","Fisetin","Flavonoids","polyphenols","NOT_YET_RECRUITING","2026-06-25",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":23},"2026-07",{"date":46,"type":23},"2027-02",{"name":48,"class":49},"Nutraland USA, Inc.","INDUSTRY",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":20,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100644843","effects-of-miricell-supplementation-on-biomarkers-of-healthy-aging-and-autophagy-100644843","NCT07675200","Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy","INCLUSION CRITERIA:\n\n* Provide voluntary signed and dated informed consent.\n* Be in fair health as determined by medical history and routine blood chemistries.\n* Age between the ages of 40 and 70 (inclusive).\n* Body weight of at least 110 pounds.\n* Normotensive (seated, resting systolic blood pressure \\\u003C140 mm Hg and diastolic blood pressure \\\u003C 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.\n* Normal seated, resting heart rate (\\\u003C90 per minute).\n* Willing to duplicate their previous 24-hour diet, refrain from alcohol for 24 hours, exercise for 24 hours prior to each trial, caffeine for 12 hours prior to each trial, and fast for 10 hours prior to each of the treatments.\n* Participant agrees to maintain existing dietary and physical activity patterns throughout the study period.\n* Participant is willing and able to comply with the study protocol.\n* If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study.\n* Able to provide an adequate blood draw.\n\nEXCLUSION CRITERIA:\n\n* Use of probiotics, postbiotics or antibiotics within the past month.\n* A history of unstable or new-onset cardiovascular\u002Fcardiorespiratory, liver, or renal disease.\n* The participant's alcohol consumption is more than two standard alcoholic drinks per day or more than 10 drinks per week or has a history of drug\u002Falcohol abuse or dependence.\n* History of diabetes (any form) or any endocrine disorder.\n* Fasting blood sugar of \\> 125 mg\u002FdL.\n* Current smokers who smoke 11 or more cigarettes per day (i.e. light smokers will be enrolled if they meet all other criteria).\n* History of hyperparathyroidism or an untreated thyroid disease.\n* History of malignancy in the previous five years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).\n* Chronic inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's Disease, ulcerative colitis, lupus, HIV\u002FAIDS, etc.).\n* Previous medical diagnosis of gout or fibromyalgia.\n* Any female who is pregnant, trying to become pregnant, is less than\u002For equal to 120 days postpartum, or any current women who are nursing.\n* Women who participate in this study must agree to the use of contraception for the duration of the study, and any sexually active woman will have to take a negative pregnancy test prior to enrolling. Women of childbearing age (any woman prior to menopause), regardless of their use of contraception, will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent.\n* Known allergy or sensitivity to any ingredient in the test formulations as listed on the product label.\n* Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.","40 Years",{"count":22,"type":23},[26],"The goal of this clinical trial is to learn if a dietary supplement called Miricell works to improve cellular health and signs of healthy aging in adults. It will also learn about the safety of Miricell.\n\nThe main questions it aims to answer are:\n\n* Does Miricell improve markers of autophagy, which is the body's natural process for recycling damaged cells?\n* Does Miricell support brain health, metabolic health, and visible signs of aging?\n* What medical problems, if any, do participants experience while taking Miricell?\n\nResearchers will compare Miricell to a placebo (a look-alike capsule that contains no active ingredients) to see if Miricell works better to support healthy aging.\n\nParticipants will:\n\n* Take either one Miricell capsule or a placebo every day for 12 weeks with a morning meal.\n* Visit the research clinic four times over the course of the study for checkups and tests.\n* Complete memory and thinking tests, track their daily physical activity, and give blood samples to measure health changes.",[62,30],"Autophagy",[64,65,66,67,68],"Spermidine","Polyamines","Cognitive Function","Miricell(R)","Cellular Health","RECRUITING","2026-06-23",{"date":72,"type":42},"2026-06-30",{"date":74,"type":42},"2026-01-09",{"date":76,"type":23},"2026-09",{"name":48,"class":49},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":24,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":50},"100642223","multivitamin-and-mineral-supplementation-and-healthy-aging-100642223","NCT07642869","Multivitamin and Mineral Supplementation and Healthy Aging","The Impacts of Multivitamin and Mineral Supplementation on Cellular Metabolism and Healthy Aging","MiMIC","Inclusion Criteria:\n\n1. IPAQ-SF categorical score of low or moderate physical activity (indicating sedentary lifestyle).\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Between 40-60 years of age\n4. BMI ≥18.5 and ≤32 kg\u002Fm2\n5. Weight stable for the prior 6 weeks\n\nExclusion Criteria:\n\n1. Is pregnant or nursing.\n2. Current smoker.\n3. Diabetes (FPG \\> 180 mg\u002FdL or A1c\\>8)\n4. Heart or cardiovascular condition, including coronary artery disease, congestive heart failure, diagnosed abnormality of heart rhythm, atrial fibrillation and\u002For a history of myocardial infarction\n5. Cancer or history of cancer within the past 5 years\n6. Sensory or physical impairment that would prevent participation\n7. Parkinson's disease, multiple sclerosis or other neurological condition, including a previous stroke, that may be causing impaired muscle function or mobility\n8. Consistent use of any multivitamin and mineral supplement use, or any supplement that may interfere with measurements or biological outcomes (including but not limited to: NAD+ supplements, MitoQ)\n9. Individuals with drug interactions as determined by the study physician","60 Years",{"count":88,"type":23},150,[26],"The goal of this study is to determine the impact of MVM supplementation on clinical and biochemical markers associated with healthy aging, with a particular focus on mitochondrial function and metabolism. Specifically, changes in mitochondrial respiration using isolated blood cells will be measured. This method has been used to compare with various other age-related markers of health such as physical function, gait speed, and resting metabolic rate. It is hypothesize that MVM supplementation will impact the function of blood cells. MVM supplementation impacts other markers of health, including serum nutrient levels, metabolomic profiles, physical function, and skeletal muscle composition and quality will be explored. These comprehensive assessments will provide insights into the potential benefits of MVM supplementation for healthy aging and address critical gaps in our understanding of its immediate effects. Further, this study will aid in the understanding of how multivitamin supplements can support heathy aging in mid-life adults, a key time to start including wellness programs in people's lives.\n\nThe study cohort will consist of 150 sedentary men and women aged 40-60-years of age. A double-blind, three-arm, placebo-controlled randomized clinical trial will be conducted. Participants will receive a daily oral tablet containing one of two possible formulations of vitamins and minerals or a placebo. The three groups will be MVM \"GOLD\" blend formula, the US Restage MVM \"US CORE\", and the placebo group.",[30,92],"Multivitamin and Mineral Supplementation",[94,95,96,97,98,99],"Multivitamin and mineral supplements","Supplements","Cellular metabolism","healthy aging","mitochondria","Respirometry","2026-06-10",{"date":102,"type":42},"2026-06-15",{"date":104,"type":42},"2025-09-05",{"date":106,"type":23},"2026-12",{"name":108,"class":109},"University of California, San Diego","OTHER",{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":118,"minAge":119,"maxAge":86,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":50},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820","NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)","FEMALE","18 Years",{"count":121,"type":23},140,[123],"PHASE1","The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[126,127,128,129,130,131,132,30,133,134,135,136,137],"Breast Pain","Mastalgia","Back Pain","Back Pain, Low","Neck Pain","Chest Pain","Activity, Motor","Weight, Body","Inflammation","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","2026-05-28",{"date":140,"type":42},"2026-06-02",{"date":142,"type":42},"2026-05-17",{"date":144,"type":23},"2029-09",{"name":146,"class":109},"University of Houston",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":17,"sex":18,"minAge":153,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":24,"phases":156,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":50},"100640391","assessing-the-influence-of-habitual-beef-intake-on-key-molecular-markers-of-brain-health-100640391","NCT07623785","Assessing the Influence of Habitual Beef Intake on Key Molecular Markers of Brain Health","Inclusion Criteria:\n\nAdults aged 65 years and older.\n\nGenerally healthy with no acute illnesses.\n\nFluent in English.\n\nWilling to consume lean beef and dairy products (cottage cheese and whey protein) daily during the intervention phases.\n\nWilling to maintain current, habitual diet, physical activity levels, and body weight throughout the study.\n\nWilling to fast for 12 hours prior to clinical visits and provide blood, urine, stool, and saliva samples.\n\nExclusion Criteria:\n\nDiagnosed with Alzheimer's disease, Parkinson's disease, or other severe cognitive disorders.\n\nHistory of gastrointestinal diseases (e.g., Crohn's disease, celiac disease) or major gastrointestinal surgery.\n\nUncontrolled diabetes, severe liver or kidney disease, or a recent cardiovascular event (within the past 6 months).\n\nAllergies or severe intolerances to beef or dairy, or adherence to a strict vegetarian or vegan diet.\n\nBody weight fluctuation of \\>5% within the past 3 months.\n\nUse of systemic antibiotics within the 2 months prior to baseline.\n\nCurrent heavy smoking or excessive alcohol consumption.","65 Years",{"count":155,"type":23},20,[26],"his study investigates whether eating lean beef every day can help support brain health and healthy aging in older adults. As people age, protecting memory and cognitive function becomes increasingly important. Lean beef is a rich source of essential nutrients-such as vitamin B12, iron, zinc, and creatine-that are known to support brain function. However, the direct biological effects of a beef-rich diet on brain health markers are not fully understood.\n\nIn this study, researchers will recruit 20 generally healthy older adults (aged 65 and older) to participate in a dietary feeding trial. Participants will complete two separate 2-week dietary phases. During one phase, participants will consume 5.5 ounces (156 grams) of provided lean beef daily. During the other phase, they will consume an iso-caloric, protein-matched, non-beef control food daily. A two-week \"washout\" period, where participants return to their normal diets, will separate the two phases to ensure there are no overlapping effects.\n\nResearchers will collect blood, urine, stool, and saliva samples at the beginning and end of each 2-week dietary phase. These samples will be analyzed to see if the lean beef diet improves specific biological markers in the blood related to memory, nerve protection, and overall brain aging. Ultimately, the findings from this study will help determine if incorporating lean beef into a regular diet can be a natural, food-based strategy to help preserve neurological health in older adults.",[30,159,160,161,162],"Brain Health","Cardiometabolic Health","Normal Aging","Cognitive Decline Prevention in Robust Older Adults",[164,165,166,167,168,169,170,171,172,173,174,175],"lean beef","red meat","dietary intervention","brain biomarkers","p-tau217","amyloid beta","bdnf","lipidomics","older adults","neuroprotection","nutrition","metabolomics",{"date":177,"type":42},"2026-06-03",{"date":177,"type":23},{"date":180,"type":23},"2027-07-31",{"name":182,"class":109},"South Dakota State University",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":17,"sex":18,"minAge":191,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":24,"phases":194,"briefSummary":195,"conditions":196,"keywords":201,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":50},"100640034","sheba-healthspan-research-population-sharp-trial---sheba-longevity-center-diagnostic-and-intervention-protocol-to-lower-biological-age-in-older-adults-100640034","NCT07596576","Sheba Healthspan Research Population (SHARP) Trial - Sheba Longevity Center Diagnostic and Intervention Protocol to Lower Biological Age in Older Adults","Sheba Healthspan Research Population (SHARP) Trial","SHARP","Inclusion Criteria:\n\n* Healthy older adults \\>50 years old men and women\n\nExclusion Criteria:\n\n1. A former diagnostic of a significant cognitive reduction (MoCa score \\\u003C 24 ).\n2. Former diagnosis of neurodegenerative disease as Alzheimer's disease, Parkinson's disease, Lewy body dementia.\n3. Former diagnosis of psychiatric disease.\n4. In the past two years, underwent chemotherapy or radiation therapy.","50 Years",{"count":193,"type":23},1500,[26],"Background: Population aging is accelerating rapidly in Israel and worldwide, necessitating adaptation of the healthcare system and considering new approaches that serve the needs of older adult populations.\n\nWorking hypothesis and aims: We hypothesize that a personalized health and behavior intervention program will decrease the biological age as assessed by several biological aging clocks and improve functional and cognitive performance among older adults.\n\nMethods: We propose to conduct a randomized study among healthy community-dwelling elderly subjects (\\>50 years old). The study will include an extensive aging assessment and imaging protocol (baseline assessment), including comprehensive physical, functional, sensory, cognitive, and mental assessment. Each participant in the intervention group will receive a personalized intervention program based on an integrative systems approach analysis. In addition, a uniquely developed application will track compliance and monitor physiological data through a provided wearable device. The control group will be assessed at baseline without receiving an intervention program. Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol. About 1,500 subjects will be recruited to participate in the study.\n\nExpected results: Obtaining data at two points will allow us to examine efficiency and compliance with a personalized intervention program based on integrative systems analysis models. We expect biological age, general well-being, and various clinical and psychosocial outcomes in the intervention group will decrease and improve compared to the control group.\n\nStudy importance and relevance: The obtained results may help establish evidence-based healthy aging diagnostics protocols and an effective personalized intervention program that might be applied, with proper modifications, to national healthcare organizations for the general older adult population. In addition, to provides a scientific basis on which policymakers and intervention programs can rely to develop national guidelines for promoting extended health.",[30,197,198,199,200],"Healthspan","Biological Age","Intrinsic Capacity","Immunaging",[202,203,204,205,206],"healthy longevity","healthspan","geromedicine","biological age","health trajectories","2026-05-18",{"date":209,"type":42},"2026-05-19",{"date":211,"type":42},"2024-03-01",{"date":213,"type":23},"2027-12-01",{"name":215,"class":216},"Sheba Medical Center","OTHER_GOV",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":17,"sex":18,"minAge":225,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":230,"conditions":231,"keywords":238,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":262,"locationsCount":4},"100639073","meva-cognitive-wellness-platform-study-for-adults-100639073","NCT07595250","MEVA Cognitive Wellness Platform Study for Adults","Phase 1 Validation Study of the MEVA Cognitive Wellness Platform","MEVA","Inclusion Criteria:\n\n* Adults aged 55 to 75 years\n* Community-dwelling (living independently in the community)\n* English fluency sufficient for informed consent, task instructions, and questionnaires\n* Able to provide informed consent using teach-back method\n* Able to use a computer or tablet for simple tap or drag interactions\n* Functional vision sufficient for on-screen tasks with usual corrective lenses\n* Functional hearing sufficient for spoken instructions with or without hearing aids\n* Interest in cognitive wellness and personal well-being\n* Available for baseline visit and possible retest visit approximately 14 days later\n* Transportation to study site or ability to participate remotely if permitted by protocol\n* Assistive devices and accommodations are permitted\n\nExclusion Criteria:\n\n* Severe visual impairment preventing completion of digital tasks\n* Severe motor impairment preventing interaction with tablet or web application\n* Known diagnosis of moderate or severe dementia, or inability to comprehend consent and task instructions\n* Current participation in another cognitive training or technology intervention study likely to confound outcomes\n* Recent hospitalization, emergency room visit, or acute exacerbation of a medical or psychiatric condition within the past 30 days that would impede study participation\n* Current substance use disorder likely to interfere with study adherence or completion\n* Recent intensive use of a similar structured cognitive wellness or brain training application","55 Years","75 Years",{"count":228,"type":23},100,"OBSERVATIONAL","The goal of this observational study is to evaluate the reliability, usability, and feasibility of the MEVA Cognitive Wellness Platform in community-dwelling adults aged 55 to 75.\n\nThe main questions it aims to answer are:\n\nHow consistent is the MEVA Global Cognitive Index when participants complete the MEVA activities again approximately 14 days later? How usable and acceptable is the MEVA platform for older adults in community settings? What completion rates, data quality patterns, and participant feedback are observed during use of the platform?\n\nParticipants will:\n\nComplete a baseline study visit lasting approximately 45 to 60 minutes Complete a 7-activity digital cognitive wellness battery Answer questionnaires about usability, technology acceptance, and wellness experience Complete the Saint Louis University Mental Status (SLUMS) examination as an exploratory comparison measure If selected for the retest group, return approximately 14 days later to complete the MEVA activities again\n\nMEVA is being evaluated as a cognitive wellness platform. It is not intended to diagnose, treat, prevent, screen for, or monitor any disease or medical condition.",[232,30,233,234,235,236,237],"Cognitive Wellness","Age-Related Cognitive Change","Aging","Cognitive Change","Health Behavior","Primary Care",[239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256],"Cognitive wellness","Healthy aging","Health equity","Test-retest reliability","Community-dwelling older adults","Primary care","Digital wellness","Older adult engagement","Psychometrics","Usability","Community health","Wellness tracking","Cognitive engagement","Adult development","General wellness","Montessori-informed activities","Technology acceptance","Exploratory convergent validity",{"date":258,"type":42},"2026-05-20",{"date":260,"type":23},"2026-05",{"date":106,"type":23},{"name":263,"class":49},"Mentage LLC",{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":17,"sex":18,"minAge":86,"maxAge":4,"enrollmentInfo":271,"targetDuration":272,"studyType":229,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":50},"100610829","digital-technology-for-active-and-healthy-ageing-in-taiwan-100610829","NCT07232667","Digital Technology for Active and Healthy Ageing in Taiwan","Healthy Taiwan Cultivation Plan: Building an Active-ageing Lifestyle in Rural Taiwan Through Integrating Novel Healthcare Technology - From Mitigating Digital and Health Literacy Gap, Establishing a Mobile Interactive Pro-active-ageing Information Platform, to Exploring Multi-dimensional Digital Biomarkers of Ageing","Inclusion Criteria:\n\n1. Currently living or receiving care in a stable environment for at least four weeks prior to enrollment:\n\n   * For community-based participants: must have resided at the same address for ≥4 weeks.\n   * For day-care participants: must have attended activities at the same dementia or elderly day-care center for ≥4 weeks.\n2. Able and willing to participate in the study procedures.\n3. Informed consent must be obtained before participation.\n\n   * If the participant's cognitive function has declined to a level that prevents self-consent, written consent will be obtained from a legally authorized representative or primary caregiver.\n\nExclusion Criteria:\n\n1. Unstable physical or psychological condition that makes participation unsafe, as determined by a clinical investigator - e.g., acute delirium or current respiratory infection (including COVID-19).\n2. Any known allergy or skin sensitivity to the materials used in the Geneactiv actigraphy device or iCue sensor pad.\n3. Any other medical, neurological, or behavioral condition deemed unsuitable for participation by the study physician.",{"count":121,"type":23},"2 Weeks","Taiwan is entering a super-aged society in 2025, with more than 20% of the population aged 65 years or older. This rapid demographic shift, combined with increasing rates of chronic diseases, frailty, and dementia, has created growing challenges for healthcare and caregiving systems. Yunlin County, particularly its coastal region, has been one of Taiwan's earliest super-aged areas, showing higher rates of diabetes (10.5%), hypertension (28%), hyperlipidemia (26%), dementia (8%), and depression (12%) compared with national averages. Lifestyle factors such as tobacco (30%), betel nut (8%), and alcohol (15%) use are also more prevalent among local residents.\n\nFrom 2022 to 2024, health screenings at CMU Beigang Hospital revealed a 36.1% abnormality rate among 12,222 visits, while another 5,965 assessments from the county's ICOPE program showed similarly high rates. Many older adults, particularly retired agricultural and fishing workers, experience sedentary lifestyles and polypharmacy-related risks, which worsen frailty, insomnia, depression, and cognitive decline. Low general and digital health literacy further limits their ability to adopt preventive behaviors, forming a vicious cycle between poor health and aging.\n\nTo address these challenges, the Ministry of Health and Welfare launched the \"Healthy Taiwan Cultivation Plan.\" In alignment with this initiative, this project-led by CMU Beigang Hospital in collaboration with the National Health Research Institutes-aims to develop a wearable- and mobile-based health promotion model for rural older adults. The study will integrate research-grade actigraphy (Geneactiv), a mobile health platform (\"iMED\"), and the in-bed sensor iCue to monitor behavior, promote active aging, and enhance health and digital literacy. Ultimately, this project seeks to establish Taiwan's first integrated digital aging database and identify digital biomarkers for predicting cognitive and functional decline in older adults.",[30,275],"Digital Health Literacy",[277,278,279,240,280,281,282],"Elderly people","Wearable technology","Digital health literacy","Health literacy","Digital gap","Digital biomarkers","2026-05-15",{"date":207,"type":42},{"date":286,"type":42},"2026-04-22",{"date":288,"type":23},"2029-12-31",{"name":290,"class":109},"China Medical University Hospital",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":17,"sex":18,"minAge":153,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100637398","computerized-cognitive-training-in-healthy-older-adults-and-mild-cognitive-impairment-100637398","NCT07598409","Computerized Cognitive Training in Healthy Older Adults and Mild Cognitive Impairment","Computerized Executive Function Training in Healthy Older Adults and Individuals With Mild Cognitive Impairment: Transfer Effects on Memory and Emotional Outcomes. A Randomized Controlled Trial","COGNI-AGE","Inclusion Criteria:\n\n1. adults 65 years of age and older;\n2. spanish speakers;\n3. residents in Spain (urban and rural communities);\n4. elderly population that does not have dementia or other major diagnosed uncontrolled neurological disorders;\n5. the initial cognitive state will be determined by a global screening test, the Lobo's Mini Cognitive Examination, that is, the spanish version of the Mini-Mental State Examination (MMSE); and 6) all participants must provide their signed written informed consent indicating that the individual has been informed of the relevant aspects of the study (and may withdraw from the study at any time if they so request).\n\nExclusion Criteria:\n\n1. Older adults who obtain scores indicative of severe impairment (to be determined for low MEC scores that are suggestive of incipient dementia) or whose medical condition prevents them from participating safely;\n2. diagnosis of dementia (e.g., Alzheimer's disease or other);\n3. uncontrolled active major psychiatric illness (major depression, schizophrenia, etc.);\n4. significant uncontrolled neurological conditions or history (e.g., Parkinson's disease, stroke, severe traumatic brain injury);\n5. uncontrolled decompensated chronic medical conditions (e.g., diabetes, cardiovascular disease) that may affect cognition or attendance at sessions; and 6) severe uncorrected sensory disabilities (e.g., blindness or severe hearing loss) that interfere with the performance of tasks on tablets.",{"count":300,"type":23},156,[26],"The overall objective of this study is to assess the effect of an adaptive computerized cognitive training program for executive functions (CogniFit platform) on improving these functions in older adults, both healthy and with mild cognitive impairment (MCI), as well as to examine the potential transfer effects of this training on memory. Additionally, determine the impact of the intervention on the emotional symptoms, behavioral disorders, or quality of life of the participants.",[304,30],"Mild Cognitive Impairment (MCI)",[306,307,308,309,310,311,312,313,314,315,316],"Computarized Cognitive Training","Healthy Cognition","Mild Cognitive Impairment","Older adults","Cognition","Executive functions","Transfer","Emotional symptoms","Behavioral disorders","Quality of life","Memory","2026-05-13",{"date":258,"type":42},{"date":320,"type":42},"2025-06-04",{"date":322,"type":23},"2028-08",{"name":324,"class":109},"Universidad Antonio de Nebrija",2,{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":17,"sex":18,"minAge":191,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":24,"phases":335,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":50},"100636576","exoskeleton-assisted-mobility-in-aging-and-in-parkinsons-disease-100636576","NCT07567482","Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease","Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease: A Mixed-Methods Study of Effectiveness and Acceptability","Participants with Parkinson's disease\n\nInclusion Criteria:\n\n* Ability to walk for at least 30 minutes with or without minimal aid\n* Diagnosis of idiopathic Parkinson's disease\n* Hoehn and Yahr stage 1 to 4\n\nExclusion Criteria:\n\n* Height smaller than 152 cm\n* Severe vascular conditions of the lower limbs that may limit mobility or pose a risk.\n* Presence of any implantable or external life-sustaining medical device such as a pacemaker\n* Severe osteoporosis or high risk of fractures\n* Contra-indication to the required physical effort\n* Severe cognitive impairment (MoCA \\\u003C 21)\n* Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility, other than Parkinson's disease.\n\nHealthy elderly participants without Parkinson's disease\n\nInclusion Criteria:\n\n* Ability to walk for at least 30 minutes with or without minimal aid\n* Age ≥ 65 years old\n\nExclusion Criteria:\n\n* Height smaller than 152 cm\n* Severe vascular conditions of the lower limbs that may limit mobility or pose a risk.\n* Presence of any implantable or external life-sustaining medical device such as a pacemaker\n* Severe osteoporosis or high risk of fractures\n* Contra-indication to the required physical effort\n* Severe cognitive impairment (MoCA \\\u003C 21)\n* Presence of neurological disorders, lower-limb injuries, or other conditions interfering with mobility",{"count":334,"type":23},26,[26],"This study will evaluate whether a wearable robotic exoskeleton can improve mobility, balance, and walking in healthy older adults and in individuals living with Parkinson's disease, populations at high risk of falls and mobility limitations. Participants will attend two laboratory sessions. The first session includes clinical assessments, fitting and familiarization with the exoskeleton, and interviews to explore user perceptions. The second session involves performing functional mobility tasks (e.g., walking, standing, turning) with and without the exoskeleton and under different assistance levels, while movement is measured using wearable sensors.\n\nThe study will assess the immediate effects of the exoskeleton on mobility, compare assistance levels, identify which participants benefit most, and explore user experience and acceptability. Findings will help inform the development and implementation of assistive technologies to support mobility in healthy aging and in individuals with Parkinson's disease.",[338,30],"Parkinson's Disease (PD)",[340,341,342,343,344,345,346],"Exoskeleton","Mobility","Rehabilitation","Parkinson's Disease","Walking","Balance","Risk of falls","2026-05-11",{"date":317,"type":42},{"date":350,"type":42},"2026-04-30",{"date":352,"type":23},"2026-11",{"name":354,"class":216},"Centre intégré de santé et de services sociaux de l'Outaouais",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":17,"sex":18,"minAge":86,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":50},"100568198","swallowing-impairments-in-adults-with-and-without-alzheimers-disease-100568198","NCT06678100","Swallowing Impairments in Adults With and Without Alzheimer's Disease","Prevalence and Care Partner Burden of Individuals With Alzheimer's Disease","Inclusion criteria for AD cohort:\n\n1. adult ≥60 years old\n2. diagnosis of AD by a neurologist (confirmed with imaging, spinal tap, behavioral testing)\n3. no prior history of other neurological diseases (aside from stroke which has resolved with no current symptoms)\n4. no prior history of respiratory diseases\n5. no prior history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n6. consuming some form of oral intake\n7. able to follow basic directions\n8. able\u002Fwilling to provide consent\u002Fassent.\n\nExclusion Criteria for AD Cohort:\n\n1. individual \\\u003C60 years old\n2. Diagnosis of another type of dementia\n3. History of neurological\u002Frespiratory diseases\n4. History of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n5. not consuming any oral intake\n6. Unable to follow basic directions\n7. Unable to provide consent based on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC), score \\\u003C15 OR provide assent and a legal guardian\u002Fhealth care decision maker provides consent.\n\nInclusion criteria for care partners of individuals with AD will be:\n\n1. care partner of an individual with AD\n2. willing to complete questionnaires\u002Fparticipate in an interview.\n\nExclusion Criteria for Caregivers of Individuals with AD:\n\n1. not the primary caregiver of an individual with AD\n2. unwilling to complete questionnaires\u002Fsemi-structured interview\n\nInclusion criteria for community-dwelling adults will be:\n\n1. adult ≥60 years old\n2. no prior history of neurological diseases (aside from stroke which has resolved with no current symptoms)\n3. no prior history of respiratory diseases\n\n3\\) no prior history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region 4) no prior history of swallowing difficulties based on participant report. 5) Score ≥25th percentile based on sex\u002Fage\u002Feducation\u002Frace on the Montreal Cognitive Assessment (MOCA)\n\nExclusion Criteria for Healthy Cohort:\n\n1. individual \\\u003C60 years old\n2. history of neurological disease\n3. history of respiratory disease\n4. history of head and neck surgery\u002Fhead and neck cancer\u002Fradiation to head and neck region\n5. history of swallowing difficulties\n6. Score \\\u003C25th percentile based on sex\u002Fage\u002Feducation\u002Frace on the Montreal Cognitive Assessment (MOCA)",{"count":363,"type":23},240,"This research study is investigating whether people with Alzheimer's disease (AD) experience more changes to swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe AD is high (85-93%), yet little is known about how swallow function evolves throughout the disease course in people with AD. The overall objective of this study is to evaluate swallowing function in adults with and without Alzheimer's disease. The investigator will also be involving the primary caregivers of individuals with Alzheimer's that are enrolled in the study to better understand the impact of swallowing impairments on the primary caregivers of those with Alzheimer's Disease.\n\nHealthy adults and individuals with Alzheimer's disease will:\n\n* undergo tests of cough and swallow function\n* undergo tests of grip and tongue strength\n* complete questionnaires\n\nCaregivers of individuals with Alzheimer's disease will also complete questionnaires.",[366,367,30,368],"Alzheimer Disease","Caregiver Burden","Dysphagia","2026-05-06",{"date":371,"type":42},"2026-05-08",{"date":373,"type":42},"2025-04-21",{"date":375,"type":23},"2028-02",{"name":377,"class":109},"Vanderbilt University Medical Center",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":24,"phases":388,"briefSummary":389,"conditions":390,"keywords":395,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":325},"100509058","african-americans-aa-communities-speak-100509058","NCT05908487","African Americans (AA) Communities Speak","African Americans (AA) Communities Speak: Partnering With AA in the North and South to Train Palliative Care Clinicians to Address Interpersonal and Systemic Racism and Provide Culturally Aligned Care.","AACS","Inclusion Criteria: Aim 1.1\n\nPerson with serious Illness:\n\n* Self-identified as African American (i.e., born, raised, and lived primarily in the US)\n* Non-Hispanic or Latino\n* Age ≥60 years\n* English-speaking\n* Has been diagnosed with a condition that fits into one of 3 illness paradigms including cancer, cardiac disease, pulmonary disease, neuro-degenerative disease, renal disease, stroke, sepsis, hepatic disease)\n* Callahan Six-Item Screener score ≥4\n* Able to complete baseline surveys.\n\nBereaved family member:\n\n* Self-identified as African American (i.e., born, raised, and lived primarily in the US)\n* Non-Hispanic or Latino\n* Age ≥60 years\n* English-speaking\n* Loved one dies in the last 12 months and was diagnosed with a condition that fits into one of 3 illness paradigms including cancer, cardiac disease, pulmonary disease, neuro- degenerative disease, renal disease, stroke, sepsis, hepatic disease)\n* Callahan Six-Item Screener score ≥4\n* Able to complete baseline surveys.\n\nExclusion Criteria\n\nPerson with serious illness:\n\n-Cannot be receiving hospice care\n\nBereaved Family Member:\n\n-Cannot be a paid \"sitter\"\n\nInclusion Criteria: Aim 1.2\n\nBereaved Family member:\n\n* Self-identified as African American (i.e., born, raised, and lived primarily in the US)\n* Non-Hispanic or Latino\n* Age ≥60 years\n* English-speaking\n* Loved one dies in the last 12 months and was diagnosed with a condition that fits into one of 3 illness paradigms including cancer, cardiac disease, pulmonary disease, neuro- degenerative disease, renal disease, stroke, sepsis, hepatic disease)\n* Callahan Six-Item Screener score ≥4\n* Able to complete baseline surveys\n\nPastors:\n\n* Self-identifying as African American\n* White, Non-Hispanic or Latino\n* Sged ≥18 years old.\n\nInclusion Criteria: Aim 3\n\nClinician eligibility:\n\n* Practice at a University of Alabama at Birmingham (UAB) or Montefiore\u002FEinstein site that provides care to patients eligible for outcomes surveys\n* At least 3 months of clinical practice at the study site prior to the intervention training to measure pre-intervention patient surveys\n\nExclusion criteria:\n\n-Lack of at least 3 months of clinical practice at the study site prior to the intervention training.\n\nPatient eligibility:\n\n* Self-identified as African American (i.e., born, raised, and lived primarily in the US)\n* Non-Hispanic or Latino, 3. age ≥60 years\n* English-speaking\n* Has been diagnosed with a condition that fits into one of 3 illness paradigms including cancer, cardiac disease, pulmonary disease, neuro-degenerative disease, renal disease, stroke, sepsis, hepatic disease)\n* Callahan Six-Item Screener score ≥4\n* Able to complete baseline surveys.\n\nExclusion criteria include:\n\n-Currently receiving hospice care.\n\nFamily member eligibility:\n\n* Age ≥ 18 years\n* English-speaking\n* Community-dwelling\n* Unpaid care provider of a person with a serious illness.\n\nExclusion criteria: 1. Cannot be a paid \"sitter\".",{"count":387,"type":23},60,[26],"African Americans are less likely to receive quality end-of-life (EoL) care. Addressing disparities in EoL care will need efforts to support a better understanding of African American patients' EoL cultural values and preferences for EoL communication and the impact of historical and ongoing care delivery inequities in healthcare settings.\n\nOur proposed \"Caring for Older African Americans\" training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and an implicit bias recognition and management training to mitigate bias in goals of care communication.",[30,391,392,393,394],"Health Knowledge, Attitudes, Practice","Social Responsibility","Care Eliciting Behavior","Racism, Systemic",[396],"goal concordant care older African American CBPR end-of-life","2026-05-05",{"date":399,"type":42},"2026-05-07",{"date":401,"type":42},"2025-02-27",{"date":403,"type":23},"2028-07",{"name":405,"class":109},"University of Alabama at Birmingham",{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":17,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":414,"targetDuration":416,"studyType":229,"phases":4,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":50},"100639408","russ-age-creating-of-a-biological-age-calculator-and-study-of-aging-phenotypes-in-the-russian-population-100639408","NCT07574359","RUSS-AGE: Creating of a Biological Age Calculator and Study of Aging Phenotypes in the Russian Population","RUSS-AGE, CREATING OF A BIOLOGICAL AGE CALCULATOR AND STUDY OF AGING PHENOTYPES IN THE RUSSIAN POPULATION","RUSS-AGE","Inclusion Criteria: Signing the informed consent form to participate in the study.\n\nParticipant's age was 18 years or older at the time of inclusion in the study.\n\n\\-\n\nExclusion Criteria:\n\n1. Refusal to participate in the study or to provide informed consent.\n2. History or medical records indicating the presence of infectious diseases (Hepatitis C, Hepatitis B, including HBsAg carrier status, HIV infection).\n3. Presence of an acute illness\u002Fcondition, exacerbation of a chronic disease, or surgical intervention within the last month prior to study inclusion.\n4. Lack of remission from an oncological disease or ongoing anti-tumor therapy initiated less than three years prior to study inclusion.\n5. Severe cognitive or sensory impairments and mental disorders that, in the investigator's opinion, preclude adequate communication with the subject.\n6. Severe forms of chronic non-communicable diseases: life-threatening cardiac arrhythmias, chronic heart failure NYHA Class III-IV, left ventricular ejection fraction \\\u003C40%, ischemic heart disease CCS Class III-IV, chronic kidney disease Stages 4-5, type 1 diabetes mellitus, type 2 diabetes mellitus with terminal stages of complications, systemic connective tissue diseases, chronic obstructive pulmonary disease with respiratory failure of Grade 1 or higher, bronchial asthma requiring glucocorticosteroid therapy, osteoarthritis Kellgren-Lawrence Grade IV, body mass index (BMI) ≥40 kg\u002Fm², as well as documented history of myocardial infarction (MI) or acute cerebrovascular accident (stroke).\n7. Pregnancy or lactation (breastfeeding).\n8. Any other factors that, in the investigator's opinion, may preclude the participant's inclusion in the study.\n\n   Additional exclusion criteria for participants undergoing stool sample collection:\n9. Use of systemic antibiotics for 3 or more days within the 3 months prior to the study start.\n10. Any invasive procedures on the large intestine within the last 3 weeks prior to the study start.",{"count":415,"type":23},3500,"2 Years","This is a multi-center, cross-sectional, observational study aimed at developing biological age calculators specifically for the Russian population investigating various aging phenotypes.\n\nAging is a complex process that varies greatly between individuals, meaning that chronological age does not always reflect one's biological health status. The primary goal of this study is to identify and analyze a comprehensive set of markers (including socioeconomic factors, lifestyle, physical parameters, cognitive function, and laboratory biomarkers) that best reflect the aging process. Using this data, researchers will create a mathematical model to estimate a person's \"biological age.\"\n\nThe study plans to enroll at least 3,500 male and female volunteers aged 18 years and older from across Russia. Participants will be divided into 5-year age groups (e.g., 18-24, 25-29, up to 90+ years) to ensure broad representation.\n\nParticipation involves a single visit to a clinical center. During this visit, participants will undergo:\n\nInterview and questionnaires (assessing health history, lifestyle, socioeconomic status, diet, sleep, and quality of life).\n\nPhysical examination and anthropometric measurements (height, weight, blood pressure, grip strength).\n\nFunctional and cognitive tests (e.g., walking speed, balance tests, memory and attention tasks tailored to age).\n\nCollection of biomaterials: blood (50 ml), urine, and stool samples for extensive laboratory analysis, including routine tests and specialized aging biomarkers. Part of the biomaterials will be biobanked for future scientific research.\n\nInstrumental examinations for a subset of participants: Depending on the center's capabilities and the study protocol, some participants may also undergo additional assessments such as densitometry (bone density scan), bioimpedance analysis (body composition), and brain MRI.\n\nThe results are expected to lead to the creation of a validated biological age calculator for the Russian population. This tool could help identify targets for interventions to promote healthy aging and, in the future, potentially predict the risk of developing age-related chronic diseases.",[30,419],"Biomarkers",[205,421,422,423,424,425,97,426],"aging biomarkers","aging clock","biological age calculator","phenotypic age","aging phenotype","machine learning in aging","2026-05-04",{"date":399,"type":42},{"date":430,"type":42},"2023-01-12",{"date":432,"type":23},"2030-09",{"name":434,"class":109},"Pirogov Russian National Research Medical University",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":17,"sex":18,"minAge":86,"maxAge":442,"enrollmentInfo":443,"targetDuration":4,"studyType":24,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":50},"100442999","effect-of-hypoxic-conditioning-on-cerebrovascular-health-in-the-elderly-100442999","NCT05048680","Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly","HYPOXAGE","Inclusion Criteria:\n\n* 60 to 80 years of age;\n* Being physically inactive (less than 150 min\u002Fweek of moderate to intense physical activity);\n* No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program;\n* Health coverage;\n* Being able to provide written fully informed consent.\n\nExclusion Criteria:\n\n* Body-mass index \\>30 kg\u002Fm2;\n* Smoking (\\> cigarettes\u002Fday);\n* Alcohol use (\\> 10g\u002Fday);\n* Mental disorder or history of mental disorder;\n* Beta-blockade treatment;\n* Inability or refusal to provide informed consent;\n* No health coverage\n* People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials;\n* People deprived of freedom by judicial or administrative decision;\n* People subject to legal protection, who cannot be included in clinical trials.","80 Years",{"count":444,"type":23},64,[26],"In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.",[448,449,450,451,234,452,30],"Hypoxia","Cerebral Hypoxia","Brain Diseases","Exercise","Cognitive Decline",{"date":371,"type":42},{"date":455,"type":42},"2021-10-13",{"date":76,"type":23},{"name":458,"class":109},"University Hospital, Grenoble",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":17,"sex":18,"minAge":86,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":24,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":474,"leadSponsor":476,"locationsCount":50},"100636944","adjuvant-nitrate-to-boost-exercise-induced-health-benefits-in-older-adults-100636944","NCT07572266","Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults","BOOST-X","Inclusion Criteria:\n\n1. Male or female aged 60 years or older\n2. Free of chronic disease or disorder that would preclude full participation or have the potential to confound results\n3. No structured exercise program (2 or more bouts\u002Fwk) within previous 12 months\n4. Cognitively capable of providing informed consent\n\nExclusion Criteria:\n\n1. BMI ≥ 30.0 kg\u002Fm2\n2. Neurodegenerative disease\n3. Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and\u002For physical performance testing\n4. Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.\n5. Resting blood pressure \\\u003C90\u002F60 mmHg or \\>160\u002F95 mmHg\n6. Uncontrolled hypertension\n7. Any current cardiovascular disease or cardiopulmonary instability\n8. Recent cardiovascular event or procedure within the preceding 6 months\n\n   1. If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure\n   2. Any mechanical valve replacement that requires continuous warfarin anti-coagulation\n9. Anemia: Hgb \\\u003C11.0 (♂),10.0 (♂) gm\u002Fdl\n10. Diabetes with HgbA1c \\>7.0% or fasting blood glucose ≥ 130 mg\u002Fdl\n11. Liver disease with ALT \\> 52 U\u002Fl)\n12. Chronic kidney disease (eGFR \\\u003C 45)\n13. Any current infectious disease\n14. Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)\n15. Life expectancy \\\u003C 1 year Medications \u002F lifestyle\n16. Insulin sensitizing\u002Fblood glucose lowering agents such as metformin\n17. Currently on or have used GLP-1 agonist or other metabolic \u002F weight loss drug in previous 12 weeks\n18. Use of nitrate medications\n19. High dose statin (≥40 mg\u002Fd simvastatin equivalence)\n20. Chronic corticosteroids\n21. Testosterone or other anabolic\u002Fandrogenic hormone therapy\n22. Lidocaine allergy\n23. Regular tobacco use and\u002For vaping \\> 1\u002Fwk\n24. Use of cannabis \\> 1\u002Fwk\n25. Excessive alcohol consumption (3 drinks\u002Fd or 7 drinks\u002Fwk for females; 4 drinks\u002Fd or 14 drinks\u002Fwk for males)\n26. Use of illicit drugs (e.g., cocaine, opioids)\n27. Unable to commit to \\~4 months required to complete the study",{"count":467,"type":23},226,[26],"Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments to compromise intrinsic capacity and healthspan. Exercise is the only multipotent treatment with promise to mitigate many of the aging hallmarks, but there is substantial variability in individual exercise responsiveness. Thus, the investigators approach to boosting exercise responsiveness in aging is to combine an exercise training prescription containing both endurance and resistance training (in alignment with DHHS guidelines) with a nitrate-enriched dietary supplement to augment the cellular, tissue, and systemic adaptations that induce myriad health benefits of exercise in older adults.",[234,471,30],"Aging Well",{"date":399,"type":42},{"date":260,"type":23},{"date":475,"type":23},"2031-05",{"name":477,"class":109},"Florida Institute for Human and Machine Cognition",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":17,"sex":18,"minAge":191,"maxAge":20,"enrollmentInfo":485,"targetDuration":4,"studyType":24,"phases":487,"briefSummary":488,"conditions":489,"keywords":492,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":499,"leadSponsor":500,"locationsCount":50},"100628039","collagen-peptides-and-cellular-aging-100628039","NCT07456449","Collagen Peptides and Cellular Aging","Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Intervention Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Middle-aged and Older Adults","Inclusion Criteria:\n\n* Adults aged 50-70 years; both male and female participants are eligible\n* Body mass index (BMI) 25-30 kg\u002Fm²\n* Low to moderate physical activity: not meeting current WHO recommendations (\\\u003C150 minutes\u002Fweek) or ≤2 sessions\u002Fweek structured training\n* Able to live independently and mobile in daily life\n* No regular resistance training within the past 6 months\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases)\n* Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants)\n* Acute infections or surgeries within the last 3 months\n* Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D)\n* Participation in another clinical study within the last 3 months\n* Vegetarian or vegan diet (product contains animal-derived collagen)",{"count":486,"type":23},125,[26],"The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease).\n\nMain questions it aims to answer are:\n\nDoes six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health?\n\nResearchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers.\n\nParticipants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation\u002Fredox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality.",[490,30,491],"Longevity","Biological Ageing",[234,493,95,494,197,495],"Collagen","Patient Care","Cellular aging","2026-04-28",{"date":397,"type":42},{"date":286,"type":42},{"date":322,"type":23},{"name":501,"class":109},"University of Vienna",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":17,"sex":18,"minAge":508,"maxAge":442,"enrollmentInfo":509,"targetDuration":4,"studyType":24,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":518,"leadSponsor":520,"locationsCount":4},"100310982","the-role-of-gaba-mediated-inhibition-in-multisensory-temporal-processing--postural-control-in-older-adults-100310982","NCT03328455","The Role of GABA-mediated Inhibition in Multisensory Temporal Processing & Postural Control in Older Adults","Inclusion Criteria:\n\n* Age between 65 and 80 (elderly group) and between 20 and 35 (young group)\n\nExclusion Criteria:\n\n* History of epilepsy, stroke, Parkinson's disease, Alzheimer's disease, attention deficit-hyperactivity disorder\n* History of head injury with loss of consciousness, brain surgery, or psychiatric disorders\n* Early dementia or cognitive impairment\n* Serious vision problems (including best-corrected binocular visual acuity worse than 20\u002F25)\n* Uncorrected hearing problems (pure tone threshold \\> 40 dB for 1000-2000 Hz)","20 Years",{"count":510,"type":23},50,[26],"In recent years evidence has accumulated on the association between age-related decline in multisensory temporal processing and postural control. This proposed project aims at examining GABA-mediated inhibition as the potential mechanism behind this link. Our overarching hypothesis is that changes in the excitatory-inhibitory balance with a reduction of GABAergic inhibition is a common mechanism underlying age-related multisensory and postural deficits potentially mediated by age-related reduction in network segregation. To test this hypothesis, we will assess the relationship between age-related multisensory\u002Fpostural deficits and age-related reduction in GABA concentration in related brain areas and probe the role of GABA-mediated inhibition using cognitive training that specifically targets inhibitory functions. Our multimodal approach is innovative, and findings from this study has the potential to lead to the development of safe and effective rehabilitation protocols for older adults with impaired multisensory temporal integration and postural control.",[30],"2026-04-27",{"date":516,"type":42},"2026-05-01",{"date":213,"type":23},{"date":519,"type":23},"2031-11-30",{"name":521,"class":109},"University of Nevada, Reno",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":226,"enrollmentInfo":530,"targetDuration":4,"studyType":24,"phases":532,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":50},"100624304","ivs-1-probiotic-intervention-targeting-biological-aging-in-midlife-adults-100624304","NCT07407894","iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults","VITAL-Age Trial (iVS-1 Investigation for Targeting Aging and Longevity)","VITAL","Inclusion Criteria:\n\n* Aged 40-75 years.\n* BMI: 20-34.9 kg\u002Fm².\n* Able and willing to sign informed consent and participate for the study duration.\n\nExclusion Criteria:\n\n* Chronic disease history (liver, kidney, heart).\n* Current pregnancy and\u002For lactating.\n* Colonoscopy and\u002For its preparation within 4 weeks of screening.\n* Those who intend to have children during study period.\n* Current probiotic, prebiotics and\u002For metabolic-altering supplement use.\n* Those who are unable to cooperate with investigators and testing.\n* Known history of cancer and\u002For ongoing cancer treatments.\n* Abuse of drugs, alcohol, tobacco, nicotine and other substances.\n* History of cardiac diseases: atherosclerosis, heart failure, unstable angina, stable angina, etc., and chronic hypoxic disease: emphysema, pulmonary heart disease and others related.\n* History of chronic and major GI disease (pancreatitis, IBS, and IBD) and intestinal surgeries.\n* Type 1 or 2 diabetes mellitus.\n* Poorly controlled chronic diseases (hypertension, hyperlipidemia) that are clinically unstable.\n* Vulnerable groups, including clinically ill, mentally ill, cognitively impaired, minors, and illiterate etc.\n* Significant weight loss (\\>20%) in prior one month.\n* Conditions affecting safety or outcome integrity.",{"count":531,"type":23},80,[26],"This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.",[30,535],"Anti Aging",[537,538,234,539,540,541,197],"Bifidobacterium adolescentis","iVS-1","Geroscience","Gut Microbiome","Probiotic","2026-04-21",{"date":286,"type":42},{"date":545,"type":42},"2026-02-01",{"date":547,"type":23},"2027-01",{"name":549,"class":49},"Synbiotic Health",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":17,"sex":18,"minAge":191,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":559,"briefSummary":560,"conditions":561,"keywords":562,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":325},"100632577","effectiveness-of-intensive-tutoring-vs-flexible-self-learning-on-digital-health-literacy-and-self-efficacy-for-my-health-bank-app-use-among-adults-over-50-100632577","NCT07515495","Effectiveness of Intensive Tutoring vs. Flexible Self-Learning on Digital Health Literacy and Self-Efficacy for \"My Health Bank\" App Use Among Adults Over 50","Effectiveness of Intensive Tutoring vs. Flexible Self-Learning on Digital Health Literacy and Self-Efficacy for \"My Health Bank\" App Use Among Adults Over 50: A Randomized Controlled Trial Using AI-Co-Created Materials","Inclusion Criteria:\n\n* Participants aged 50 years and older.\n* Possession of a smartphone with basic operational skills (e.g., unlocking the phone, making calls, and using LINE).\n* Self-reported lack of familiarity with the \"My Health Bank\" App (used less than 3 times or never used in the past year).\n* Proficiency in listening, speaking, reading, and understanding Mandarin Chinese.\n\nExclusion Criteria:\n\n* Regular users of the \"My Health Bank\" App (used 3 times or more in the past year).\n* Severe cognitive impairment identified through brief cognitive screening, the participant unable to follow instructions or complete questionnaires.\n* Smartphone operating system is too outdated to support the installation of the \"NHI App\" (National Health Insurance App).\n* Inability to complete the App download and installation process independently or with family assistance (e.g., lost App Store\u002FGoogle Play password, insufficient storage space).",{"count":558,"type":23},235,[26],"The purpose of this study is to evaluate the effectiveness of two different educational models in improving the use of the \"My Health Bank\" App (a Personal Health Record system in Taiwan) among adults aged 50 and older. As Taiwan's population ages, digital health management has become essential, yet older adults often face a \"digital divide.\" Participants will be randomly assigned to either a \"Intensive Guided Learning group\" (receiving one-on-one human instruction) or a \"Flexible Self-study group\" (using self-learning materials co-created with Generative AI). The study aims to compare the outcomes of these two groups in terms of enhancing digital health literacy, self-efficacy, and actual App usage behavior to identify more effective and scalable digital health education strategies.",[275,30],[563,564,565,566],"eHealth Literacy","Health Self-Efficacy","My Health Bank","Randomized Controlled Trial","2026-04-07",{"date":569,"type":42},"2026-04-13",{"date":571,"type":42},"2026-04-02",{"date":573,"type":23},"2027-03-09",{"name":575,"class":109},"Tri-Service General Hospital",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":586,"conditions":587,"keywords":590,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":50},"100604580","plant-based-diets-and-healthy-aging-100604580","NCT07151365","Plant-based Diets and Healthy Aging","Plant-based Diets and Healthy Aging - the Tzu Chi Aging Study (TCAS)","TCAS","Inclusion Criteria:\n\n* Age 40 years or older.\n* Volunteers of the Tzu Chi Foundation.\n* Participating in the 2-day comprehensive health examination program.\n\nExclusion Criteria:\n\n* Pregnant individual.\n* Diagnosed with dementia or poor cognition resulting in inability to answer questionnaires.",{"count":585,"type":23},5000,"This prospective study investigates the health effects of vegetarian and plant-based diets in middle-aged and older adults in Taiwan, specifically, recruiting 5000 Tzu Chi volunteers. Previous Tzu Chi cohorts found vegetarian diets were protectively associated with incidences of diabetes, stroke, gout, cataracts, insomnia, and gallstones, while reducing healthcare costs. The study also aims to clarify dietary patterns-particularly plant-based and vegetarian diets-and determine how potential deficiencies or excesses of various nutrients influence common aging-related health issues, including healthy cognitive decline, sarcopenia, and the risk of age-related diseases, in order to inform dietary and lifestyle recommendations that promote healthy aging and maintain physical function.",[30,588,589,452],"Sarcopenia","Frailty",[591,592,240,593,588,589],"Vegetarian diets","Plant-based diets","Cognitive decline","2026-04-06",{"date":596,"type":42},"2026-04-08",{"date":598,"type":42},"2025-09-01",{"date":600,"type":23},"2028-12-31",{"name":602,"class":109},"National Health Research Institutes, Taiwan",{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":17,"sex":18,"minAge":119,"maxAge":191,"enrollmentInfo":610,"targetDuration":4,"studyType":24,"phases":612,"briefSummary":613,"conditions":614,"keywords":616,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":50},"100476683","neuromodulation-and-fatigue-100476683","NCT05487131","Neuromodulation and Fatigue","Neuromodulation and Its Effects on Muscle Activity and Fatigue","Inclusion Criteria:\n\nHealthy individuals between 18 and 50 years old\n\nExclusion Criteria:\n\nMetal implants or joint replacement. Presence of neuromuscular disease. Skin hypersensitivity.",{"count":611,"type":23},40,[26],"In this project, we aim to determine any potential effects of a weak electrical current applied to the neck or thoracic area on functional capacity and muscle activation. Healthy individuals will participate in one familiarization followed by up to 6 experimental sessions. Fatigability and motor function will be assessed in each test session.",[30,615],"Fatigue",[617,618,619],"Transcutaneous spinal direct current stimulation","TsDCS","Fatigability","2026-04-03",{"date":622,"type":42},"2026-04-09",{"date":624,"type":42},"2023-06-03",{"date":626,"type":23},"2027-12",{"name":628,"class":109},"University of Oklahoma",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":153,"enrollmentInfo":637,"targetDuration":4,"studyType":24,"phases":639,"briefSummary":640,"conditions":641,"keywords":643,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":50},"100610761","the-effect-of-urolithin-a-mitopure-supplementation-on-muscle-strength-in-healthy-middle-aged-adults-100610761","NCT07231783","The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults","A Confirmatory, Randomised, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Effects of a Dietary Supplement Containing Urolithin A (Mitopure®) on Muscle Strength and Performance in Healthy Middle-Aged Adults","ATLAS 2","Inclusion Criteria:\n\n* 1\\. Be able to give written informed consent.\n* 2\\. Be between 40 to 65 years of age, inclusive.\n* 3\\. Has a BMI between 25.0 and 34.9 kg\u002Fm2.\n* 4\\. Low physical activity levels as assessed by the International Physical Activity Questionnaire (IPAQ).\n* 5\\. Participants with low VO2 peak (defined as \\\u003C35 mL\u002Fkg\u002Fmin via the ergometer prior to baseline).\n* 6\\. Willing to avoid exercising 48-h prior to study visits and maintain low physical activity status for the duration of the study.\n* 7\\. Willing to avoid caffeine and other stimulants (e.g., energy drinks) 12-h before exercise as per study guidelines.\n* 8\\. Willing to consume the Study Product daily for the duration of the study.\n\nExclusion Criteria:\n\n* 1\\. Participants who are pregnant or wish to become pregnant during the study or who are lactating and\u002For currently breastfeeding.\n* 2\\. Participants currently of biological childbearing potential, but not using a continuous effective method of contraception, as outlined below:\n\n  * a. Complete abstinence from intercourse two weeks prior to administration of the Study Product, throughout the clinical study, until the completion of follow-up procedures or for two weeks following discontinuation of the Study Product in cases where Participant discontinues the study prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding two weeks when they present to the clinic for the final visit).\n  * b. Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that Participant.\n  * c. Sexual partner(s) is\u002Fare exclusively female.\n  * d. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm), tubal ligation, or contraceptive pill. The Participant must be using this method for at least one week prior to and one week following the end of the study.\n  * e. Use of any intrauterine device (IUD) or contraceptive implant. The Participant must have the device inserted at least two weeks prior to the first screening visit, throughout the study, and two weeks following the end of the study.\n* 3\\. Participants with history of drug and\u002For alcohol abuse at the time of enrolment. (Drinks more than nationally recommended units per week (\\>11 units for women; \\>17 units for men); alcohol\u002Fsubstance abuse disorder).\n* 4\\. Participants consuming large quantities of pomegranate juice or walnuts or frequent consumers of raspberries, strawberries or cloudberries (2-week washout).\n* 5\\. Chronic nicotine use.\n* 6\\. Participants who are unable to swallow capsules.\n* 7\\. Is hypersensitive to or has dietary restrictions for any of the components of the Study Product e.g., gelatine\n* 8\\. Unstable body weight or recent participation in a weight loss program (within 12-weeks prior to screening).\n* 9\\. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:\n\n  * a. Major illness\u002Fsurgery in the 12-weeks prior to screening\n  * b. Diagnosed cardiovascular disease (NHYA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmia, uncontrolled hypertension)\n  * c. Diagnosed liver disease (cirrhosis, end stage liver disease)\n  * d. Diagnosed kidney disease (stage 3b or 4 chronic kidney disease, or kidney failure)\n  * e. Diagnosed gastrointestinal disease (IBS\u002FIBD, diarrhoea, Acid Reflux)\n  * f. Uncontrolled thyroid conditions\n  * g. Uncontrolled diabetes\n  * h. Metallic implants\n  * i. Conditions requiring chemotherapy or immunotherapy.\n* 10\\. Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:\n\n  * a. Statins or other medications known to impair mitochondrial function.\n  * b. Anxiolytics, antidepressants, sedative hypnotics (in the 8 weeks prior to visit 1)\n  * c. Antipsychotics, monoamine Oxidase Inhibitors (in the 8 weeks prior to visit 1)\n  * d. Oral anti- infective (antibiotics, antivirals, antifungals) for acute infections (in the 12-weeks prior to visit 1)\n  * e. Proton pump inhibitors (PPIs) (in the 4 weeks prior to visit 1)\n  * f. Corticosteroids (\\> 5mg per day in the past 4 weeks prior to visit 1)\n  * g. GLP-1 agonists (in the 8 weeks prior to visit 1)\n* 11\\. Current or recent (in the past 6-weeks prior to Visit 1) use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited supplements include:\n\n  * a. Mitopure® containing supplements\n  * b. Supplements for muscle strengthening\u002Fbuilding or mitochondrial boosting supplements (e.g. high protein, Vitamin B3 \\[and precursors\\], L-carnitine, CoQ10, NAD+, resveratrol)\n* 12\\. Blood donation in the 8-weeks prior to screening.\n* 13\\. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.\n* 14\\. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study (physical or muscle performance), the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.",{"count":638,"type":23},120,[26],"This is a randomised, double-blind, placebo-controlled, parallel study to assess the effects of Urolithin A (Mitopure®) supplementation on muscle strength and performance in healthy middle-aged adults. Participants will be randomized to consume Mitopure® (500 mg), Mitopure® (1000 mg), or placebo once daily for 6 months.",[30,642],"Muscle Function",[644],"Urolithin A","2026-03-30",{"date":647,"type":42},"2026-03-31",{"date":649,"type":42},"2025-12-10",{"date":651,"type":23},"2027-10-31",{"name":653,"class":49},"Amazentis SA",{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":4,"eligibilityCriteria":660,"healthyVolunteers":17,"sex":18,"minAge":191,"maxAge":226,"enrollmentInfo":661,"targetDuration":4,"studyType":24,"phases":662,"briefSummary":663,"conditions":664,"keywords":665,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":50},"100555750","impact-360-for-healthy-agers-100555750","NCT06516146","Impact 360 for Healthy Agers","Impact 360 Study for Healthy Agers","Inclusion Criteria:\n\n* Participants who are able to complete questionnaires and follow directions for interventions\n* Have access to a smartphone that can support the Fitbit app\n\nExclusion Criteria:\n\n* Any neurological disease\u002Fdisorder diagnosis (Ex: Parkinson's Disease, Multiple Sclerosis, Traumatic Brain Injury, Brain lesion, Stroke, etc)\n* Any chronic medical condition which would affect ability to participate in exercise\n* Any contraindication for exercise based on the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) and medical clearance form\n* Participants who were told by a medical doctor that they need to be medically supervised for exercise\n* Montreal Cognitive Assessment (MoCA) scores \\\u003C21\u002F30\n* Significant cognitive impairment, depression, or eating disorder\n* Any contraindication to MRI scanning; such as implanted metal clips or wires (see list below)\n* Participants currently doing 180 minutes or more of moderate-vigorous intensity exercise per week AND either of the following:\n* Completion of an Mindfulness-Based Stress Reduction course OR; Score \\>8\u002F15 in the Mediterranean-Dietary Approaches to Stop Hypertension (DASH) Intervention for Neurodegenerative Delay (MIND) Diet Questionnaire\n* Significant or unstable cardiovascular or respiratory disease\n* Severe\u002Fmultiple head trauma(s)\n* Subjects who are pregnant or breastfeeding\n* Subjects with a history or major episodes of drug or alcohol abuse\n* Chronic\u002Facute bacterial\u002Fviral infection\n* GI cancer\n* Inflammatory bowel disease\n\nExclusion for MRI scanning:\n\n* Individuals weighing \\> 400 lbs (limit of MRI machine)\n* Artificial heart valve\n* Brain aneurysm clip\n* Electrical stimulator for nerves or bones\n* Ear or eye implant\n* Implanted drug infusion pump\n* Coil, catheter, or filter in any blood vessel\n* Orthopedic hardware (artificial joint, plate, screws)\n* Other metallic prostheses\n* Shrapnel, bullets, or other metal fragments\n* Surgery or tattoos (including tattooed eyeliner) in the last six weeks\n* Brain surgery\n* Have a cardiac pacemaker, wires or defibrillator\n* Have had an injury where a piece of metal lodged in the eye or orbit\n* Have a ferromagnetic aneurysm clip",{"count":387,"type":23},[26],"The Impact 360 study will evaluate the effects of a combined intervention of exercise, mindfulness, and nutrition on 8 key indicators of health and the mechanisms that drive these changes. 60 subjects aged 50 to 75 without a current diagnosis of a brain disorder will be recruited. This study will follow a partial crossover design. All participants will receive the intervention. Participants randomized into the intervention group after their baseline screening will receive the 6-month intervention. Those randomized into the waitlist group will complete another assessment at the end of the 6-month care as usual phase before receiving the intervention.",[30],[451,666,667,668],"Mindfulness","Microbiome","Well-Being","2026-03-19",{"date":671,"type":42},"2026-03-23",{"date":673,"type":42},"2024-01-24",{"date":675,"type":23},"2028-01-05",{"name":677,"class":109},"University of British Columbia",{"id":679,"slug":680,"hasResults":12,"nctId":681,"briefTitle":682,"officialTitle":682,"acronym":683,"eligibilityCriteria":684,"healthyVolunteers":17,"sex":18,"minAge":508,"maxAge":685,"enrollmentInfo":686,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":688,"conditions":689,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":50},"100542926","uncovering-the-cognitive-and-neural-mechanisms-underlying-cognitive-time-100542926","NCT06349213","Uncovering the Cognitive and Neural Mechanisms Underlying Cognitive Time","TIMES","Inclusion Criteria:\n\n1. Membership of a social security scheme or beneficiary of such a scheme.\n2. At least 7 years' schooling.\n3. Acceptance and signature of the informed consent form\n4. Fluency in French (as assessed by the project leader)\n5. Age between 20 and 35 years inclusive for young healthy subjects, and between 60 and 85 years inclusive for elderly healthy subjects.\n6. Effective contraception for women of childbearing age: Contraception will be considered effective from the moment the participant declares taking an oral contraceptive, the presence of an IUD, diaphragm or contraceptive implant, or the performance of a tubal ligation or sterilisation.\n7. Absence of global cognitive deficit attested by a score on the MOCA scale greater than or equal to 26\u002F30.\n\nExclusion Criteria:\n\n1. Persons under guardianship, curators or safeguard of justice.\n2. Pregnant women, women in labor and nursing mothers\n3. Chronic neurological conditions\n4. Uncorrected visual difficulties\n5. Encephalitis\n6. Endocrine or liver disease\n7. History of head trauma with loss of consciousness lasting more than one hour\n8. History of cancer in the last 5 years, with the exception of squamous cell carcinoma of the skin\n9. Presence or history of chronic alcoholism or drug addiction\n10. Presence of clinically significant major psychiatric disorders (according to DSM-IV-TR criteria) or symptoms that could affect the participant's ability to complete the research.\n11. Use of medications that may modulate the dopaminergic system (psychotropic, with the exception of sleeping pills or occasional use of anxiolytics, as decided by the principal investigator).\n12. Contraindications to MRI examination (pregnancy; pacemaker or neurosensory stimulator or implantable defibrillator; clip on an aneurysm or clip on a vascular malformation of the brain; intraocular or cerebral ferromagnetic foreign body; prosthesis or mobilizable ferromagnetic metal object or splinter; cochlear implant ; peripheral stimulator; neurosurgical ventriculoperitoneal shunt valves; permanent eyelid or lip make-up; jewelry or piercing that cannot be removed; certain tattoos depending on the type of ink, size and location; automated injection devices such as insulin pumps, blood glucose sensors, claustrophobia).\n13. Radiotracer contraindications: Hypersensitivity to product excipients, chronic alcoholism, kidney disease.\n14. Participation in research involving exposure to ionizing radiation (nuclear medicine or radiology examinations) in the year preceding inclusion or during a period of exclusion from other research.","85 Years",{"count":687,"type":23},130,"Time processing, the ability to process and encode temporal information, is essential for cognitive functioning and for a large number of daily life activities. In particular, the processing of durations of several seconds is central to cognition, impaired in several pathologies, and has been associated with cognitive changes with advancing age. While behavioral studies have been conducted to specify the neural bases of temporal cognition and their association with other cognitive functions, the mechanisms underlying age-related changes, and individual differences, remain unknown. The project will characterize ageing effects on timing mechanisms and their neural underpinnings. Building on recent advances from neuroscience and age-related cognitive changes, the project focuses on the precision of duration processing, that declines with age, and the associated neural bases. Participants will perform a duration judgement task while (a) electroencephalography, and (b) functional magnetic resonance imaging activity are simultaneously recorded to investigate age effects on structural and functional network connectivity. In addition, striatal dopamine will be measured using a FDOPA PETscan. Evaluation of other temporal cognition processes and general cognition will also be performed. This combination offers a unique opportunity to accurately specifying the neurophysiological underpinning of aging effects on time processing changes. This project will further our understanding of the variability of cognitive performance with advancing age, and contribute to identifying new measures of temporal impairments.",[30],"2026-03-10",{"date":692,"type":42},"2026-03-11",{"date":694,"type":42},"2024-11-20",{"date":696,"type":23},"2030-11-01",{"name":698,"class":216},"Institut National de la Santé Et de la Recherche Médicale, France",{"id":700,"slug":701,"hasResults":12,"nctId":702,"briefTitle":703,"officialTitle":704,"acronym":705,"eligibilityCriteria":706,"healthyVolunteers":17,"sex":18,"minAge":191,"maxAge":226,"enrollmentInfo":707,"targetDuration":4,"studyType":24,"phases":709,"briefSummary":710,"conditions":711,"keywords":712,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":717,"lastUpdatePostDateStruct":718,"startDateStruct":719,"completionDateStruct":721,"leadSponsor":722,"locationsCount":724},"100601469","study-evaluating-the-effect-of-humiome-post-lb-on-stress-anxiety-and-cognition-in-aging-adults-100601469","NCT07110896","Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults","A Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults","AnexLB","Inclusion Criteria\n\n1. Participant is male or female, 50-75 years of age, inclusive.\n2. Participant has a Body Mass Index (BMI) of ≥18.5 kg\u002Fm2 to 32 kg\u002Fm2.\n3. Participant is generally in good health, as per investigator's judgement at V1.\n4. Participant has subjective mild to moderate memory complaints, as per investigator's judgement.\n5. Participant has a total score of ≥42 and ≤60 on the DASS-21 administered at V1.\n6. Participant is willing to maintain regular dietary, exercise, and allowed medication\u002Fsupplement habits and smoking and other nicotine habits (if a smoker or nicotine user) for the duration of the study.\n7. Participant understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.\n\n7\\. Participant understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator.\n\nExclusion criteria:\n\n1. Participant has a history or presence of a psychiatric or neurologic disease including epilepsy, cerebrovascular disease, traumatic brain injury, dementia, Alzheimer's Disease, clinical depression, or other clinically significant psychiatric\u002Fneurologic condition that, in the opinion of the investigator, could interfere with the interpretation of the study results.\n2. MMSE score at V1 \\\u003C 21.\n3. Chronic fatigue syndrome.\n4. Women: elevated stress and\u002For anxiety levels clearly related to the (peri) menopause complaints, as per investigator judgement\n5. Non-pharmacological or non-supplementation options for management of stress, anxiety or memory\u002Fcognitive complaints (e.g. yoga, \"brain jogging\") started within 4 weeks of screening 6. Participant has a clinically significant gastrointestinal, endocrine, cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic, or biliary disorder that, in the opinion of the investigator, could interfere with the interpretation of the study results.\n\n7\\. Participant has a condition that would likely cause immunosuppression. 8. Participant has a history of gastrointestinal surgery (cholecystectomy and appendectomy are acceptable, considering the prevalence in the age group), as per investigator judgement. 9. Participant has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and\u002For diastolic blood pressure ≥100 mm Hg) at screening.\n\n10\\. Participant has an issue with hearing or seeing that might interfere with the tasks\u002Fquestionnaires to be completed during the visits.\n\n11\\. Participant has used pre-, pro-, syn-, or post-biotic supplements within 90 days of screening.\n\n12\\. Participant has a history of using psychotropic medications (including antidepressants and tranquilizers), stimulant medications, and\u002For narcotics within 4 weeks of screening. 13. Participants has major sleep disorder (severe insomnia) based on investigator's judgment.\n\n14\\. Participant has used sleep aid medications, supplements, and\u002For products, including antihistamines, within 2 weeks of screening (washout prior to screening is allowed). Sporadic use of supplementation of melatonin, valerian, passion flower, lavender, if needed, if this has been habitually or occasionally done prior to the study, is allowed. 15. Participant has used an acid-blocking medication (e.g., proton pump inhibitor, H2 blocker) in the past 30 days prior to study. However, any ongoing use started at least 12 weeks before Visit 1 is allowed.\n\n16\\. Participant has used selective serotonin reuptake inhibitors (SSRIs) or benzodiazepines in the past 30 days. (Note: Participants will not be excluded on the basis of a well-managed depressive disorder that does not require SSRIs.) 17. Participant has a history of cancer in the prior 5 years. 18. Participant has an allergy to any components of the IP or the standardized breakfast.\n\n19\\. Individual has signs or symptoms of an active infection of clinical significance or has taken antibiotics within 30 days prior to any visit (washout is permitted for re-scheduling of the clinic visit).\n\n20\\. Participant has been exposed to any non-registered drug product within 30 days of the screening visit.\n\n21\\. Participant has a current or recent history (within 12 months of screening) or strong potential for illicit drug or excessive alcohol intake defined as \\>14 drinks per week (1 drink = 350 ml beer, 150 ml wine, or 40 ml hard liquor).\n\n22\\. Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method.\n\n23\\. Participant has a condition the investigator believes would interfere with his\u002Fher ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.",{"count":708,"type":23},236,[26],"To assess the effect of 3 months of daily consumption of a postbiotic (inactivated lactic acid bacteria) Humiome® Post LB on stress measured by the Depression Anxiety Stress Scale-21 (DASS-21) adjusted on baseline in study participants when compared to placebo",[30],[240,667,713,714,715,716],"Stress","Sleep","Anxiety","gut-brain","2026-03-09",{"date":692,"type":42},{"date":720,"type":42},"2025-08-01",{"date":352,"type":23},{"name":723,"class":49},"dsm-firmenich Switzerland AG",3]